Published in Oncotarget on May 17, 2016
Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer. Cell Cycle (2017) 0.75
LncRNA ANCR down-regulation promotes TGF-β-induced EMT and metastasis in breast cancer. Oncotarget (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Cell signaling by receptor tyrosine kinases. Cell (2010) 12.39
Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol (2005) 11.74
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 5.24
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature (2014) 3.80
The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer (2005) 3.59
Genetic control of bone formation. Annu Rev Cell Dev Biol (2009) 3.06
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev (2006) 2.87
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res (2008) 2.50
Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov (2014) 2.44
PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol (2012) 2.39
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res (2006) 2.31
Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer (1991) 2.26
Molecular mechanisms of endochondral bone development. Biochem Biophys Res Commun (2005) 2.22
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun (2014) 2.10
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol (2011) 2.09
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 1.89
The skeleton: a multi-functional complex organ: the growth plate chondrocyte and endochondral ossification. J Endocrinol (2011) 1.85
The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer (2014) 1.77
A prototype for unsupervised analysis of tissue microarrays for cancer research and diagnostics. IEEE Trans Inf Technol Biomed (2004) 1.55
The RUNX family: developmental regulators in cancer. Nat Rev Cancer (2015) 1.51
Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer (1994) 1.44
Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res (2011) 1.38
Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene (2010) 1.36
mda-9/Syntenin: a positive regulator of melanoma metastasis. Cancer Res (2005) 1.35
Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway. J Biol Chem (2004) 1.33
EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol (2011) 1.32
Gene silencing by synthetic U1 adaptors. Nat Biotechnol (2009) 1.29
Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog (2010) 1.24
Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol (2009) 1.21
Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Res (2009) 1.21
Foxo1 mediates insulin-like growth factor 1 (IGF1)/insulin regulation of osteocalcin expression by antagonizing Runx2 in osteoblasts. J Biol Chem (2011) 1.18
Drugging the undruggable: transcription therapy for cancer. Biochim Biophys Acta (2012) 1.14
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14
Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility. J Biol Chem (2011) 1.13
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res (2013) 1.13
PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med (2002) 1.11
Physical and functional interactions between Runx2 and HIF-1α induce vascular endothelial growth factor gene expression. J Cell Biochem (2011) 1.10
Runt-related gene 2 in endothelial cells: inducible expression and specific regulation of cell migration and invasion. Cancer Res (2001) 1.09
Runx2 in normal tissues and cancer cells: A developing story. Blood Cells Mol Dis (2010) 1.08
MDA-9/syntenin: a positive gatekeeper of melanoma metastasis. Front Biosci (Landmark Ed) (2012) 1.06
A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A (2009) 1.04
Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis. Cancer Lett (2008) 1.03
Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res (2011) 1.03
Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res (2009) 1.00
In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors. Cancer Res (2013) 0.97
Runx2 protein stabilizes hypoxia-inducible factor-1α through competition with von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes. J Biol Chem (2012) 0.97
Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol (2014) 0.96
Inhibition of insulin-like growth factor-1 (IGF-1) expression by prolonged transforming growth factor-β1 (TGF-β1) administration suppresses osteoblast differentiation. J Biol Chem (2012) 0.94
Runx2 regulates endochondral ossification through control of chondrocyte proliferation and differentiation. J Bone Miner Res (2014) 0.93
Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines. Front Genet (2013) 0.93
Insulin-like growth factor I-stimulated melanoma cell migration requires phosphoinositide 3-kinase but not extracellular-regulated kinase activation. Exp Cell Res (2003) 0.92
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. J Invest Dermatol (2011) 0.92
Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle (2012) 0.89
Glucose-activated RUNX2 phosphorylation promotes endothelial cell proliferation and an angiogenic phenotype. J Cell Biochem (2012) 0.88
Signalling specificity in the Akt pathway in breast cancer. Biochem Soc Trans (2014) 0.88
RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer (2015) 0.87
Transcription factor therapeutics: long-shot or lodestone. Curr Med Chem (2005) 0.86
Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Pigment Cell Melanoma Res (2014) 0.85
RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion. Cancer Lett (2014) 0.83
U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo. Mol Ther Nucleic Acids (2013) 0.81
Robot-Guided Atomic Force Microscopy for Mechano-Visual Phenotyping of Cancer Specimens. Microsc Microanal (2015) 0.76